EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...
CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant ...
Researchers from Guandong Pharmaceutical University reported on the synthesis and preclinical characterization of a series of novel long-acting peroxisome proliferator-activated receptor (PPAR) ...
T3D-959, an oral dual delta/gamma peroxisome proliferator-activated nuclear receptor (PPAR) agonist, has shown promise in a phase 2 randomized, placebo-controlled study of adults with mild-to-moderate ...
The FDA granted accelerated approval to oral elafibranor (Iqirvo) for treating primary biliary cholangitis (PBC) in adults, drugmaker Ipsen announced on Monday. A first-in-class dual peroxisome ...
Seladelpar, an investigational selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ), significantly improves liver biomarkers of disease activity and bothersome symptoms of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback